Press release
Actions to Remove Benzethonium Chloride from Ketamine Products in Favor of Safer and Superior Option in $750 Million Market, Projected to Reach $3.35 Billion by 2034: NRx Pharmaceuticals, Inc.
Image: https://www.globalnewslines.com/uploads/2025/08/1754310990.jpg$NRXP Has $7.8 Million for Clinic Acquisitions and Purchase of Kadima Neuropsychiatry Institute as Treatment Model and Leading Investigative Site for Suicidal Depression / PTSD
Actions to Remove Benzethonium Chloride from Ketamine Products in Favor of Safer and Superior Option in $750 Million Market, Projected to Reach $3.35 Billion by 2034: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
$NRXP Has $7.8 Million for Clinic Acquisitions and Purchase of Kadima Neuropsychiatry Institute as Treatment Model and Leading Investigative Site for Suicidal Depression / PTSD
* Developing NRX-101, an FDA-Designated Investigational Breakthrough Therapy for Suicidal Treatment-Resistant Bipolar Depression and Chronic Pain.
* Aiming to be the First FDA-Approved Medication to Treat Suicidal Depression
* Designed to Help Address the Needs of Over 13 Million Americans who Seriously Consider Suicide Each Year (CDC).
* Actions Taken to Request the Removal of Benzethonium Chloride from Ketamine Products in Favor of the Company's Safer and Superior Options.
* Agreement to Acquire Interest in Cohen and Associates, LLC for Network of Interventional Psychiatry Clinics.
* Applied for New Commissioner's National Priority Vouchers (CNPV) for NRX-100 With Anticipated Decisions on Drug Approval by Year-End.
* Application Under CNPV Program is Accretive to Already-Filed Abbreviated New Drug Application with Proprietary Formulation Under Priority Review Request.
* Abbreviated New Drug Application Filed for Preservative-Free IV Ketamine.
* Ketamine Market Estimated at $750 Million and Projected to Reach $3.35 Billion Globally in 2034.
* $7.8 Million Debt Financing to Fuel NRXP HOPE Clinic Acquisitions with Universal Capital, LLC.
* Added to Previously Announced Term Sheet with a Strategic Investor, NRXP HOPE Funding of $10.3 Million is Planned in Near Term.
* New Drug Application for Treatment of Suicidal Depression; Planned NDA for Accelerated Approval for Bipolar Depression in People at Risk of Akathisia.
* Accepted Non-Binding Potential Terms to License and Distribute NRX-100 Drug Providing Over $300 Million in Milestones Plus Tiered Double-Digit Royalties.
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. NRXP is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain
NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRXP is working on a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
Intravenous ketamine is widely accepted as a standard of care for acute treatment of suicidal depression, in the absence of an FDA-labeled product; the only treatment currently approved by the FDA is electroconvulsive therapy (ECT). According to the CDC, 3.8 million Americans make a plan for suicide each year.
Request to the Food and Drug Administration Seeking Removal of Benzethonium Chloride from Ketamine Products to Favor a Switch to Better Options
On August 4th NRXP announced its actions with the US Food and Drug Administration (FDA), seeking the removal of Benzethonium Chloride from ketamine sold in the United States. Benzethonium Chloride (BZT) is a preservative that is not Generally Recognized as Safe (GRAS) by the FDA for parenteral products and not Generally Recognized as Safe and Effective (GRASE) for topical products. The FDA no longer allows BZT to be used in hand cleansers and topical antiseptics and other products on the market today for safety concerns. The ketamine versions made by NRXP is BZT free and therefore presents a safer and superior option.
In June 2025 NRXP filed an Abbreviated New Drug Application with the FDA for a preservative-free preparation of ketamine, demonstrating support for 3 year room temperature stability and sterility. NRXP has similarly filed a patent on its preservative-free process, in light of prior art that suggested BZT was required for long term stability and sterility. NRXP has instituted US-based high volume manufacture, while it awaits generic approval. The Company is additionally seeking a labeled indication for the use of ketamine to treat suicidal depression through the recently-announced FDA Commissioner's National Priority Voucher Program.
Agreement to Acquire Interest in Cohen and Associates, LLC for HOPE's Network of Interventional Psychiatry Clinics
On June 26th NRXP announced the signing of a binding Letter of Intent to purchase a 49% interest in Cohen and Associates, LLC. Cohen is expected to serve as a foundational clinic for NRXP in the Sarasota-Bradenton region of western Florida.
Cohen is one of the premier Interventional Psychiatry clinics in the region. The clinic offers a full range of treatments for suicidal depression, PTSD and other CNS disorders, including ketamine, Spravato, Transcranial Magnetic Stimulation ("TMS") as well as medication management. NRXP stated that this acquisition should be immediately accretive to revenue and EBITDA.
Filing of Commissioner's National Priority Voucher Application for Intravenous Ketamine (NRX-100)
On June 23rd NRXP announced filing for the newly-announced FDA Commissioner's National Priority Voucher program on behalf of NRX-100, its patent-pending, preservative-free formulation of ketamine for intravenous use.
On June 17, 2025, FDA Commissioner Marty Makary, MD, MPH announced a new approval pathway, the Commissioner's National Priority Voucher (CPNV)1, for approval of drugs to enhance the health interests of Americans. Previously, on May 25 he identified psychedelic drugs for treatment of suicidal depression and PTSD as a national priority.2 The new voucher may be redeemed by drug developers to participate in a Commissioner-led program that shortens its review time from approximately 10-12 months to 1-2 months following a sponsor's final drug application submission.
To qualify for the CNPV, sponsors must submit the chemistry, manufacturing, controls (CMC) portion of the application and the draft labeling at least 60 days before submitting the final application. NRXP has already submitted the CMC portion for NRX-100 and received FDA feedback.
Strategic Investor Relations Partnership with astr partners
On June 16th NRXP announced a strategic investor relations partnership with astr partners, a boutique investor relations and capital advisory firm focused on the life sciences sector.
astr partners will work with the NRXP and HOPE subsidiary executive teams to execute a comprehensive investor relations program that includes investor targeting, message development, earnings preparation, conference support, and proactive investor engagement.
$7.8 Million Debt Financing to Fuel NRXP HOPE Clinic Acquisitions
On May 15th NRXP announced signing of a term sheet with Universal Capital, LLC to provide $7.8 million in acquisition capital to initiate subsidiary HOPE's planned national rollup of interventional psychiatry clinics, commencing with previously-announced acquisitions of Dura Medical, Kadima, and NeuroSpa. Together with proceeds of a previously announced strategic investment, this financing is anticipated to provide $10.3 million in acquisition capital.
HOPE's three initial acquisitions represent best-in-class clinics that offer neuroplastic treatments including NRXP ketamine and transcranial magnetic stimulation (TMS) to treat patients with severe depression, PTSD, and related central nervous system conditions. Neuroplastic treatments represent a rapidly emerging class of interventions that cause the growth of new connections (synapses) between brain cells that have been shown in multiple clinical trials to relieve symptoms of depression and suicidality. The FDA has approved TMS devices for a number of indications and has approved a nasal form of ketamine for treatment resistant depression. HOPE's parent company, NRXP, is currently applying to the FDA for approval of intravenous preservative-free ketamine to treat suicidal depression.
For more information on $NRXP visit: https://www.nrxpharma.com/ [about:blank] and https://compasslivemedia.com/case-study/nrx-pharmaceuticals/
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Media Contact
Company Name: NRx Pharmaceuticals, Inc.
Contact Person: Matthew Duffy, Chief Business Officer
Email: Send Email [http://www.universalpressrelease.com/?pr=actions-to-remove-benzethonium-chloride-from-ketamine-products-in-favor-of-safer-and-superior-option-in-750-million-market-projected-to-reach-335-billion-by-2034-nrx-pharmaceuticals-inc]
Phone: 484 254 6134
Address:1201 Orange Street Suite 600
City: Miami
State: Florida
Country: United States
Website: https://www.nrxpharma.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. GetNews makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Actions to Remove Benzethonium Chloride from Ketamine Products in Favor of Safer and Superior Option in $750 Million Market, Projected to Reach $3.35 Billion by 2034: NRx Pharmaceuticals, Inc. here
News-ID: 4134167 • Views: …
More Releases from Getnews

SafeNest Provides Resources and Education on Domestic Violence Shelters in Las V …
Las Vegas nonprofit underscores the importance of access to safe housing and support services for survivors of domestic abuse
Image: https://www.globalnewslines.com/uploads/2025/10/51b4ac59e4136ddbe98bbf111dcc2753.jpg
SafeNest, a nonprofit organization dedicated to ending domestic and physical violence in Southern Nevada, is highlighting the critical role of a domestic violence shelter in providing safety, stability, and long-term support for survivors. Operating as a trusted domestic violence shelter in Las Vegas, SafeNest offers confidential housing, counseling, advocacy, and prevention…

Prime Secured Strengthens Omaha Businesses with Proven Managed IT and Cybersecur …
Image: https://www.globalnewslines.com/uploads/2025/10/1759522505.jpg
For years, Prime Secured has been a trusted technology partner to businesses across the greater Omaha area, delivering comprehensive managed IT services and advanced cybersecurity solutions that protect, optimize, and future-proof local organizations.
For years, Prime Secured has been a trusted technology partner to businesses across the greater Omaha area, delivering comprehensive managed IT services and advanced cybersecurity solutions that protect, optimize, and future-proof local organizations.
Omaha, NE - October 3,…

Dextra Group Announces Successful Internal Deployment of Durabar GFRP Carpet at …
Dextra Group Launches Durabar GFRP Carpet Pilot at Thailand Facility
Image: https://www.globalnewslines.com/uploads/2025/10/5576f516f167c5d5971c5e9e5feac8d8.jpg
Dextra Group [https://www.dextragroup.com/], a global leader in engineered construction products and reliable connections, today announced the pilot deployment of its patented Durabar GFRP (Glass Fiber Reinforced Polymer) carpet at the company's manufacturing facility in Thailand, advancing the material's journey from R&D to production-floor use and setting the stage for broader market rollout.
The pilot introduces Durabar into a live, heavy-duty environment…

Andre Shammas Highlights the Importance of Budgeting Support for Small Businesse …
Local Accountant Calls for Greater Awareness of Everyday Challenges Faced by Entrepreneurs
Andre Shammas, a respected accountant and tax preparer based in El Cajon, has been featured in a new in-depth interview about his career, values, and work with small businesses. In the conversation, Shammas uses his platform to raise awareness of the real challenges entrepreneurs face when it comes to staying organised with budgeting and tax preparation.
"Small business owners are…
More Releases for NRXP
Transforming Mental Health Treatments and Expanding Clinic Networks: NRx Pharmac …
Image: https://www.globalnewslines.com/uploads/2025/01/1737669812.jpg
NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP), a clinical-stage biopharmaceutical leader, is at the forefront of addressing critical mental health challenges, including suicidal depression, bipolar disorder, and PTSD. Through groundbreaking therapeutics and strategic investments, the company aims to revolutionize care for millions while delivering significant returns for investors.
A Breakthrough in Mental Health Treatment
NRX-101, the company's flagship product, is an FDA-designated investigational Breakthrough Therapy targeting suicidal treatment-resistant bipolar depression and chronic…
Acquisition of Kadima Neuropsychiatry Institute for CNS & Psychedelic Research P …
$NRXP IS Aiming to be the First FDA-Approved Medication to Treat Suicidal Depression
- Developing NRX-101, an FDA-Designated Investigational Breakthrough Therapy for Suicidal Treatment-Resistant Bipolar Depression and Chronic Pain.
- Designed to Help Address the Needs of Over 13 Million Americans who Seriously Consider Suicide Each Year (CDC).
- Kadima Neuropsychiatry Institute Targeted as First Acquisition for HOPE Subsidiary International Network of Interventional Psychiatry Clinics.
- Kadima is a Leading Investigative Site for CNS…
Substantial Funding, Debt Resolution, HOPE Dividend, Successful Clinical Trial T …
For more information on $NRXP visit: https://www.nrxpharma.com/ and https://compasslivemedia.com/case-study/nrx-pharmaceuticals/
- Developing Therapeutics for the Treatment of CNS Disorders, Specifically Suicidal Bipolar Depression, Chronic Pain and PTSD.
- Company Funded For New Drug Applications (NDAs) for NRX-100 (ketamine) and NRX-101
- Audit of HOPE Therapeutics Subsidiary Complete, SEC Filing of Spinout Planned for Current Quarter.
- Secured $10.8 - $16.3 Million Convertible-Debt Funding from an Institutional Investor.
- Retirement of Older Debt and Settlement of…
Alignment with FDA on Pediatric Study Plan and Accelerated Approval to Treat Bip …
NRXP could Realize Over $150 in Revenue Per Share, Plus HOPE Subsidiary Spinoff Moves Forward
- Developing Therapeutics for the Treatment of CNS Disorders, Specifically Suicidal Bipolar Depression, Chronic Pain and PTSD.
- Alignment on Initial Pediatric Study Plan is a Gating Requirement for Upcoming Filing of NRX-100 New Drug Application for Suicidal Depression.
- On Track to File NDA for NRX-100 in Q4 2024 & Planned PDUFA Date in Q2 2025.
-…
New Data on Infection Avoidance and Development of pH Neutral Ketamine, for Intr …
- Developing Therapeutics for the Treatment of CNS Disorders, Specifically Suicidal Bipolar Depression, Chronic Pain and PTSD.
- MOU Signed with Conversio Health with Immediate Plans to Ship IV Ketamine Product to Full Range of Customers via 503a and 503b Pharmacies.
- No Impact on Gut or Vaginal Flora - Considered Primary Causes of Pseudomembranous Colitis due to C Difficile and Vaginal Yeast Infections.
- Received FDA Qualified Infectious Disease Product (QIDP) and…
Investigation announced for Long-Term Investors in shares of NRx Pharmaceuticals …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors of NRx Pharmaceuticals, Inc.
Investors who are current long term investors in NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: NRXP stocks follows a lawsuit filed against NRx Pharmaceuticals, Inc.…